Editorial Commentary
Enhanced power bacillus Calmette-Guérin—possibly too much of a good thing
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S461-S462
.
(31 December 2019)
Editorial comment: understanding the cost of bladder preservation in muscle invasive bladder cancer—an evaluation of radical cystectomy versus trimodal therapy costs
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S463-S465
.
(31 December 2019)
PD-L1 testing in urothelial carcinoma: are we there yet?
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S466-S468
.
(31 December 2019)
Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S469-S471
.
(31 December 2019)
Non-muscle invasive bladder cancer cystoscopic surveillance: from overuse to underuse and non-adherence impact
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S472-S473
.
(31 December 2019)
Preservation of the bladder, but at what cost?
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S474-S475
.
(31 December 2019)
Magnetic resonance imaging sequences for prostate cancer triage: two is a couple, three is a crowd?
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S476-S479
.
(31 December 2019)
Neoadjuvant chemotherapy in bladder cancer: not a matter on how much but on who it is effective
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S480-S481
.
(31 December 2019)
Risk stratification system for biparametric prostate magnetic resonance imaging
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S482-S483
.
(31 December 2019)
A novel biparametric magnetic resonance imaging sequence provides a more efficient and similarly efficacious method of risk stratifying men clinically suspected of having prostate cancer
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S484-S485
.
(31 December 2019)
Bladder cancer under staging: still unavoidable?
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S486-S487
.
(31 December 2019)
Holding a MIRror up to the robustness of the prostate cancer urinary transcriptome
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S488-S490
.
(31 December 2019)
The inflammatory potential of diet and bladder cancer risk: results from a prospective cohort study
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S491-S492
.
(31 December 2019)
Challenges of urine-based molecular assays for the detection of urothelial cancer
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S493-S496
.
(31 December 2019)
A new era in the detection of urothelial carcinoma by sequencing cell-free DNA
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S497-S501
.
(31 December 2019)
Are we really seeking for equivalence?—The virtue of the robot is in technology
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S502-S504
.
(31 December 2019)
High-resolution microultrasound imaging for bladder cancer: the birth of a new diagnostic tool?
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S505-S506
.
(31 December 2019)
Patient decision aids for urinary diversion after radical cystectomy: their potential and pitfalls
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S507-S509
.
(31 December 2019)
Urinary tract infection after radical cystectomy: a vexing problem despite prophylactic antibiotics
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S510-S513
.
(31 December 2019)
The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S514-S516
.
(31 December 2019)
Bacillus Calmette Guérin in bladder cancer: is more immune stimulation better?
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S517-S520
.
(31 December 2019)
Robotic assisted radical cystectomy: insights on long term oncological outcomes from the International Robotic Cystectomy Consortium
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S521-S523
.
(31 December 2019)
Capturing recurrence in urothelial carcinoma: “more than meets the eye”
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S524-S527
.
(31 December 2019)
Hypofractionation in prostate cancer radiotherapy: a step forward towards clinical routine
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S528-S532
.
(31 December 2019)
The perils of using registry data to compare the survival and cost of radical cystectomy and trimodality therapy in bladder cancer
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S533-S537
.
(31 December 2019)
New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S538-S541
.
(31 December 2019)
Commentary: underutilization of curative-intent therapy for patients with muscle-invasive bladder cancer in Sweden mimics the United States
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S542-S545
.
(31 December 2019)
UroSEEK gene panel for bladder cancer surveillance
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S546-S549
.
(31 December 2019)
Letter to the Editor
Influence of auriculotherapy on erectile dysfunction: commentaries and perspectives
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S550-S551
.
(31 December 2019)
News
Application of the CARE guideline as reporting standard in the Translational Andrology and Urology
Translational Andrology and Urology
2019;
8
(Suppl 5)
:S552
.
(31 December 2019)
Disclosure:
The supplement was published without any sponsorship or funding.
